P
Pure Biomedicine
A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies
About Pure Biomedicine
Based in Suzhou, China, PrimeLink Bio is a biotechnology firm established in 2021, concentrated on creating advanced drug delivery systems for cancer treatments. The company operates within the drug discovery and biotechnology sectors, with a specific focus on oncology. Its business is centered around the development of a proprietary Antibody-Drug Conjugate (ADC) technology platform. This platform is designed to be both flexible and modular, enabling the synthesis of a wide array of ADC drug candidates. Through a systematic screening process, PrimeLink Bio aims to identify the most effective ADC composition for specific targets.
The company's stated mission is to develop next-generation drug delivery systems with its own global intellectual property rights to produce first-in-class and best-in-class therapeutics. The core of its technology is a hydrophilic linker that broadens the therapeutic window for targeted therapies. PrimeLink Bio is developing a pipeline of treatments, including PLBA-001 for lung cancer, PLBA-002 for ovarian cancer, and PLBA-003 for various solid tumors. The company leverages resources from both China and the United States to advance its technology and drug development programs.
As a privately held, venture capital-backed entity, PrimeLink Bio has secured funding from investors such as Fosun Health Capital, Fosun Pharma, Kaitai Capital, and Vertex Ventures China. A Series A2 funding round in May 2024 raised $2.34 million, indicating the company is in the pre-clinical trial stage. The company serves the oncology market, with the ultimate goal of providing effective treatments for cancer patients globally. Revenue generation will likely be tied to the successful clinical development and commercialization of its therapeutic pipeline, through partnerships, licensing deals, or direct sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2022 | $28M | $110M | Vertex Ventures China · Kaitai Capital · Shanghai Fosun Pharmaceutical | ↗ |
Growth signals
Latest recorded traffic for Pure Biomedicine is 530 monthly website visits, down 8.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Pure Biomedicine in the Suzhou Shi ecosystem
The Pure Biomedicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Vertex Ventures China- KCKaitai Capital
Shanghai Fosun Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pure Biomedicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pure Biomedicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








